Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

P&G's OTC Market Direction Steered By Consumers' Turn To Self-Care Solutions

Executive Summary

Firm scans health care market for OTC drug properties meeting consumers’ growing demand for non-Rx products, says CFO Jon Moeller. He says P&G is well-positioned to "brand-build" acquired assets given its distribution network in oral, personal and feminine care, and its cost-cutting capabilities.

You may also be interested in...



P&G’s Leaner, Stronger Beauty Business Drives 10% Growth

Procter & Gamble beauty sector sales grow 10% in its latest quarter on strength of anti-aging skin care products globally and across price tiers. Firm also announces to purchase First Aid Beauty, further diversifying its skin care portfolio with a lineup of products sold in specialty retail stores and priced between P&G's SK-II and Olay brands.

P&G Adds Merck's Brands, Expands Consumer Health Categories, Footprint

P&G’s planned acquisition of Merck KGaA’s consumer health care business will grow its consumer health portfolio 50%, expand its OTC drug and supplement business abroad and open up new categories.  CEO David Taylor frames the acquisition as another step in the firm's ongoing portfolio shakeup.

Technology Gap Separates OTC Drug Firms From Self-Care Sales Growth

OTC drug firms should offer more digital tools that guide consumers in product purchases, says a health care marketing executive. The American Pharmacists Association suggests firms also strengthen outreach with pharmacists.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS123833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel